Opnurasib (JDQ443, NVP-JDQ443) is a potent, mutant-selective, covalent KRAS G12C inhibitor.
JDQ443 promotes dose-dependent reductions of phosphorylated ERK (pERK) levels and the proliferation of the KRASG12C-mutated cell lines NCI-H358 and NCI-H2122 with IC50 of 18 and 63 nM, respectively. 
JDQ443 binds under the switch II loop with a novel binding mode, exploiting unique interactions with the KRAS G12C protein compared to sotorasib and adagrasib.
JDQ443 potently inhibits KRASG12C cellular signaling and proliferation in a mutant selective manner.
JDQ443 exhibits dose-dependent anti-tumor activity in mice bearing KRAS G12C mutated tumor xenografts comparable to sotorasib and adagrasib.
JDQ443 is orally bioavailable and is well-tolerated.
Combination of JDQ443 with the SHP2 inhibitor TNO155 further increases KRAS G12C target occupancy in vivo, enhanced pre-clinical anti-tumor activity, and delayed the emergence of resistance in xenografts.